Arkolith/Insider Trading/SKYE/Form 4/A

Arsenault Kaitlyn

Chief Financial OfficerSkye Bioscience, Inc. (SKYE) · full profile →Form 4/A · filed Mar 4, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 29, 2024Grant(A)25K—$0210K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 29, 2024Grant(A)75K—$075K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001516551-24-000016) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML